Published in Vaccine Weekly, August 9th, 2006
The phase 2 trial will test different vaccine dosages and schedules in 400 healthy volunteers between the ages of 18 and 55. The clinical trial is underway and will continue into 2007 at eight locations across the United States.
"An effective, licensed plague vaccine is a crucial component of U.S. biodefense initiatives," said Robert V. House, president and chief scientific officer of DVC. "Plague has been identified as a Category A bioterrorism agent by the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.